Insider Transactions in Q4 2020 at Olema Pharmaceuticals, Inc. (OLMA)
Insider Transaction List (Q4 2020)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Nov 23
2020
|
Wellington Biomedical Innovation Master Investors (Cayman) I L.P. > 10% Shareholder |
BUY
Conversion of derivative security
|
Direct |
1,725,406
+35.38%
|
-
|
|
Nov 23
2020
|
Cyrus Harmon |
BUY
Conversion of derivative security
|
Indirect |
122,028
+50.0%
|
-
|
|
Nov 23
2020
|
Cyrus Harmon |
BUY
Conversion of derivative security
|
Direct |
71,374
+6.03%
|
-
|
|
Nov 23
2020
|
Peter J. Kushner CHIEF SCIENTIFIC OFFICER |
BUY
Conversion of derivative security
|
Direct |
358,920
+11.64%
|
-
|
|
Nov 23
2020
|
Frank Mccormick Director |
BUY
Conversion of derivative security
|
Indirect |
66,326
+44.05%
|
-
|
|
Nov 23
2020
|
Frank Mccormick Director |
BUY
Conversion of derivative security
|
Direct |
152,891
+44.44%
|
-
|
|
Nov 23
2020
|
David C. Myles CH. DISCOV. & NON-CLIN DEV OFF |
BUY
Conversion of derivative security
|
Indirect |
167,677
+50.0%
|
-
|
|
Nov 23
2020
|
Andrew Rappaport |
BUY
Conversion of derivative security
|
Indirect |
448,556
+34.42%
|
-
|
|
Nov 23
2020
|
G. Walmsley Graham Director |
BUY
Open market or private purchase
|
Indirect |
1,160,000
+50.0%
|
$22,040,000
$19.0 P/Share
|
|
Nov 23
2020
|
G. Walmsley Graham Director |
BUY
Conversion of derivative security
|
Indirect |
2,583,875
+50.0%
|
-
|
|
Nov 23
2020
|
Cormorant Asset Management, LP |
BUY
Open market or private purchase
|
Indirect |
425,000
+11.5%
|
$8,075,000
$19.0 P/Share
|
|
Nov 23
2020
|
Cormorant Asset Management, LP |
BUY
Conversion of derivative security
|
Indirect |
2,845,544
+50.0%
|
-
|
|
Nov 19
2020
|
Bvf Partners L P Director |
BUY
Open market or private purchase
|
Direct |
1,135,334
+15.01%
|
$21,571,346
$19.0 P/Share
|
|
Nov 19
2020
|
Bvf Partners L P Director |
BUY
Conversion of derivative security
|
Direct |
5,216,676
+32.82%
|
-
|